Enanta Pharmaceuticals Inc (ENTA)
12.26
+0.04
(+0.33%)
USD |
NASDAQ |
Jun 25, 16:00
12.26
0.00 (0.00%)
After-Hours: 20:00
Enanta Pharmaceuticals Research and Development Expense (Annual): 163.52M for Sept. 30, 2023
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| September 30, 2023 | 163.52M |
| September 30, 2022 | 164.52M |
| September 30, 2021 | 174.11M |
| September 30, 2020 | 136.76M |
| September 30, 2019 | 142.21M |
| September 30, 2018 | 94.86M |
| September 30, 2017 | 57.45M |
| Date | Value |
|---|---|
| September 30, 2016 | 40.46M |
| September 30, 2015 | 23.19M |
| September 30, 2014 | 18.74M |
| September 30, 2013 | 16.84M |
| September 30, 2012 | 15.12M |
| September 30, 2011 | 11.55M |
| September 30, 2010 | 9.716M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
136.76M
Minimum
2020
174.11M
Maximum
2021
156.23M
Average
163.52M
Median
2023
Research and Development Expense (Annual) Benchmarks
| Artivion Inc | 28.71M |
| Nanoviricides Inc | 6.392M |
| FibroGen Inc | 282.86M |
| Corvus Pharmaceuticals Inc | 16.53M |
| Bioventus Inc | 13.45M |